Re­gen­eron and Genen­tech bat­tle for oph­thal­mol­o­gists’ affin­i­ty in Eylea HD, Vabysmo matchup

Af­ter sev­en months on the mar­ket, Re­gen­eron’s Eylea HD is al­ready mak­ing strides with oph­thal­mol­o­gists.

Ac­cord­ing to Spher­ix Glob­al In­sights’ re­search, 81% of oph­thal­mol­o­gists who use Eylea HD to treat wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) are “high­ly sat­is­fied,” which tracks close­ly to the 87% who say the same about Roche and Genen­tech’s Vabysmo, which has been on the mar­ket for about 25 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER